Global Finance News
30 Apr 2026, 17:41
GE HealthCare reported mixed first-quarter 2026 results, with solid revenue growth offset by margin pressure and lower earnings.
Revenue increased 7.4% year-over-year to $5.1 billion, supported by demand in Pharmaceutical Diagnostics, imaging, and services, with organic growth of 2.9%. Orders grew modestly by 1.1% organically, with a book-to-bill ratio of 1.07 and a backlog of $21.8 billion.
Profitability declined, as net income fell to $389 million and diluted EPS dropped to $0.85 from $1.23 a year earlier. Adjusted EBIT margin decreased to 13.5%, impacted by a supplier issue in Pharmaceutical Diagnostics, tariffs, and rising input costs such as chips, oil, and freight.
While the supplier issue has been resolved, inflationary pressures led the company to lower its full-year profit and free cash flow outlook, even as it maintained its revenue growth expectations.
GE HealthCare expects mid- to high-single-digit adjusted EPS growth for 2026, supported by pricing actions, cost controls, and continued innovation.
Source: Business Wire
Revenue increased 7.4% year-over-year to $5.1 billion, supported by demand in Pharmaceutical Diagnostics, imaging, and services, with organic growth of 2.9%. Orders grew modestly by 1.1% organically, with a book-to-bill ratio of 1.07 and a backlog of $21.8 billion.
Profitability declined, as net income fell to $389 million and diluted EPS dropped to $0.85 from $1.23 a year earlier. Adjusted EBIT margin decreased to 13.5%, impacted by a supplier issue in Pharmaceutical Diagnostics, tariffs, and rising input costs such as chips, oil, and freight.
While the supplier issue has been resolved, inflationary pressures led the company to lower its full-year profit and free cash flow outlook, even as it maintained its revenue growth expectations.
GE HealthCare expects mid- to high-single-digit adjusted EPS growth for 2026, supported by pricing actions, cost controls, and continued innovation.
Source: Business Wire
